Molecular Partners Announces all Board Proposals Approved at Annual General Meeting

Core Points - Molecular Partners AG, a clinical-stage biotech company, announced that all motions proposed by the Board of Directors at the Annual General Meeting were approved by shareholders with a wide majority [1] - Shareholders confirmed the approval of the annual review, IFRS consolidated financial statements, and the annual statements for the financial year 2024, including the decision to carry forward a net loss of CHF 50,643,414 [2] - The Board of Directors and Management Board members were granted discharge for the financial year 2024, and all members of the Board were re-elected for a one-year term [3] - KPMG AG Zurich was re-elected as statutory auditors for the financial year 2025, and Anwaltskanzlei Keller AG was elected as the independent proxy until the 2026 Annual General Meeting [4] Company Overview - Molecular Partners AG specializes in developing DARPin therapeutics, focusing on medical challenges that other drug modalities cannot address, with oncology as its main area of focus [5] - The company was founded in 2004 and operates offices in Zurich, Switzerland, and Concord, Massachusetts, USA [5]